167 related articles for article (PubMed ID: 37692846)
1. Medication guide for dose adjustment and management of cardiotoxicity and lipid metabolic adverse events of oral antineoplastic therapy.
Ramos-Ruperez E; Escudero-Vilaplana V; Ruiz-Briones P; Collado-Borrell R; Villanueva-Bueno C; Revuelta-Herrero JL; González-Haba E; Garcia-Gonzalez X; Ibañez-Garcia S; Perez-Ramirez S; Zatarain-Nicolás E; Herranz A; Sanjurjo M
Front Oncol; 2023; 13():1220305. PubMed ID: 37692846
[TBL] [Abstract][Full Text] [Related]
2. Medication guide for the perioperative management of oral antineoplastic agents in cancer patients.
Villanueva-Bueno C; Escudero-Vilaplana V; Collado-Borrell R; Giménez-Manzorro Á; Ribed A; Marzal-Alfaro B; Revuelta-Herrero JL; Gonzalez-Haba E; Herranz A; Sanjurjo M
Expert Opin Drug Saf; 2022 Jan; 21(1):107-119. PubMed ID: 34357828
[TBL] [Abstract][Full Text] [Related]
3. Oral antineoplastic agent interactions with medicinal plants and food: an issue to take into account.
Collado-Borrell R; Escudero-Vilaplana V; Romero-Jiménez R; Iglesias-Peinado I; Herranz-Alonso A; Sanjurjo-Sáez M
J Cancer Res Clin Oncol; 2016 Nov; 142(11):2319-30. PubMed ID: 27316629
[TBL] [Abstract][Full Text] [Related]
4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
5. Oral antineoplastic agents: assessment of safety and dose adjustments in clinical practice.
Escudero-Vilaplana V; Revuelta-Herrero JL; Collado-Borrell R; Marzal-Alfaro B; Gimenez-Manzorro A; Herranz-Alonso A; Sanjurjo-Saez M
Expert Opin Drug Saf; 2019 Sep; 18(9):861-868. PubMed ID: 31282227
[No Abstract] [Full Text] [Related]
6. Hypertension and QT interval prolongation associated with targeted systemic cancer therapies.
Fahey OG; Piccolo JK; Bergsbaken JJ; N Dow-Hillgartner E
J Oncol Pharm Pract; 2020 Dec; 26(8):1987-1996. PubMed ID: 32951523
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: a comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events.
Ewer MS; Suter TM; Lenihan DJ; Niculescu L; Breazna A; Demetri GD; Motzer RJ
Eur J Cancer; 2014 Aug; 50(12):2162-70. PubMed ID: 24930624
[TBL] [Abstract][Full Text] [Related]
8. Domperidone safety: a mini-review of the science of QT prolongation and clinical implications of recent global regulatory recommendations.
Buffery PJ; Strother RM
N Z Med J; 2015 Jun; 128(1416):66-74. PubMed ID: 26117678
[TBL] [Abstract][Full Text] [Related]
9. Potentially Hazardous Drug-Drug Interactions Associated With Oral Antineoplastic Agents Prescribed in Chinese Tertiary Care Teaching Hospital Settings: A Multicenter Cross-Sectional Study.
Wang H; Shi H; Wang Y; Wang N; Li Y; Yang Q; Li Y; Liu C; Zan Y; Feng S; Xie J
Front Pharmacol; 2022; 13():808848. PubMed ID: 35177990
[No Abstract] [Full Text] [Related]
10. Novel mobile application for direct communication between pharmacists and patients treated with oral antineoplastic agents.
Collado-Borrell R; Escudero-Vilaplana V; Ribed A; Jiménez RR; Peinado II; Herranz-Alonso A; Sanjurjo-Sáez M
Am J Health Syst Pharm; 2020 Aug; 77(17):1393-1402. PubMed ID: 32620958
[TBL] [Abstract][Full Text] [Related]
11. Nationwide prevalence of potential drug-drug interactions associated with non-anticancer agents in patients on oral anticancer agents in South Korea.
Song YK; Oh JM
Support Care Cancer; 2020 Aug; 28(8):3711-3720. PubMed ID: 31820128
[TBL] [Abstract][Full Text] [Related]
12. Management of QT prolongation induced by anti-cancer drugs: Target therapy and old agents. Different algorithms for different drugs.
Coppola C; Rienzo A; Piscopo G; Barbieri A; Arra C; Maurea N
Cancer Treat Rev; 2018 Feb; 63():135-143. PubMed ID: 29304463
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval).
Shah RR; Morganroth J; Shah DR
Drug Saf; 2013 May; 36(5):295-316. PubMed ID: 23620167
[TBL] [Abstract][Full Text] [Related]
14. Carfilzomib-induced Cardiotoxicity: An Analysis of the FDA Adverse Event Reporting System (FAERS).
Buck B; Kellett E; Addison D; Vallakati A
J Saudi Heart Assoc; 2022; 34(3):134-141. PubMed ID: 36127934
[TBL] [Abstract][Full Text] [Related]
15. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
[TBL] [Abstract][Full Text] [Related]
16. Cardio-oncology in Austria: cardiotoxicity and surveillance of anti-cancer therapies : Position paper of the Heart Failure Working Group of the Austrian Society of Cardiology.
Bergler-Klein J; Rainer PP; Wallner M; Zaruba MM; Dörler J; Böhmer A; Buchacher T; Frey M; Adlbrecht C; Bartsch R; Gyöngyösi M; Fürst UM
Wien Klin Wochenschr; 2022 Sep; 134(17-18):654-674. PubMed ID: 35507087
[TBL] [Abstract][Full Text] [Related]
17. Fluoropyrimidine Cardiotoxicity: Time for a Contemporaneous Appraisal.
Upshaw JN; O'Neill A; Carver JR; Dimond EP; Denlinger CS; Kircher SM; Wagner LI; Ky B; Brell JM
Clin Colorectal Cancer; 2019 Mar; 18(1):44-51. PubMed ID: 30348619
[TBL] [Abstract][Full Text] [Related]
18. The Safety of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Research.
Reed VA; Buitelaar JK; Anand E; Day KA; Treuer T; Upadhyaya HP; Coghill DR; Kryzhanovskaya LA; Savill NC
CNS Drugs; 2016 Jul; 30(7):603-28. PubMed ID: 27290715
[TBL] [Abstract][Full Text] [Related]
19. Left atrial volume in patients with HER2-positive breast cancer: One step further to predict trastuzumab-related cardiotoxicity.
Bergamini C; Dolci G; Rossi A; Torelli F; Ghiselli L; Trevisani L; Vinco G; Truong S; La Russa F; Golia G; Molino A; Benfari G; Ribichini FL
Clin Cardiol; 2018 Mar; 41(3):349-353. PubMed ID: 29569424
[TBL] [Abstract][Full Text] [Related]
20. A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology.
Maurea N; Spallarossa P; Cadeddu C; Madonna R; Mele D; Monte I; Novo G; Pagliaro P; Pepe A; Tocchetti CG; Zito C; Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e93-e104. PubMed ID: 27755247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
